PMID- 26171353
OWN - PIP
STAT- PubMed-not-MEDLINE
DCOM- 20150714
LR  - 20181113
IS  - 2251-6085 (Print)
IS  - 2251-6093 (Electronic)
IS  - 2251-6085 (Linking)
VI  - 43
IP  - 12
DP  - 2014 Dec
TI  - The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis.
PG  - 1616-26
AB  - Leviteracetam (LEV) is a novel antiepileptic drug with improved tolerance and 
      safety, while carbamazepine (CBZ) represents classical antiepileptic drugs. So 
      far, a systemic comparison of the efficacy and side effects of these two drugs is 
      lacking. A literature review on the comparison of leviteracetam versus 
      carbamazepine for patients with epilepsy was performed up to September 2013 using 
      PubMed, EMBASE, the Cochrane Library and ISI web of science. Finally, 3 
      randomized controlled trials (RCT) studies met the criteria on comparing the 
      efficacy of leviteracetam versus carbamazepine for patients with epilepsy were 
      included for meta-analysis. Stata 11.0 was used to analyze and summarize the 
      respective data. Three RCTs met the entry criteria. The relative risk (RR) and 
      95% and the confidence interval (CI) of leviteracetam versus carbamazepine for 6- 
      and 12-month seizure free intervals were 1.0 (0.91-1.10) and 0.97 (0.84-1.13), 
      respectively, for therapy discontinuation due to adverse events (AEs) were 0.62 
      (0.48-0.80) and 1.00 (0.94-2.05), respectively, and for withdrawal after 6- and 
      12-month treatment were 0.8 (0.64-0.99) and 0.87 (0.74-1.03), respectively. The 
      RR and 95% CI for occurrence of headache, fatigue, diarrhea, vertigo, 
      nasopharyngitis, depression, weight gain and rash were 0.88 (0.73-1.06), 
      1.08(0.63-1.83), 1.23 (0.66-2.28), 0.92 (0.49-1.71), 0.85 (0.59-1.22), 2.15 
      (1.26-3.68), 0.69 (0.45-1.04), 0.39 (0.23-0.68), respectively. The major outcomes 
      such as rate of seizure freedom were similar between leviteracetam and 
      carbamazepine. However, leviteracetam led to depression more frequently than 
      carbamazepine, while carbamazepine caused rash more frequently. However, the 
      limited numbers of available RCTs studies and included patients in this study 
      made our results less convincing and accurate.
FAU - Li, Zhaoxia
AU  - Li Z
AD  - Dept. of Pediatrics, the Second Hospital of Shandong University, Jinan, China.
FAU - Gao, Zhuanglei
AU  - Gao Z
AD  - Dept. of Surgery, the Second Hospital of Shandong University, Jinan, China.
FAU - Jin, Chengjuan
AU  - Jin C
AD  - Dept. of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, 
      China.
FAU - Guo, Qinghui
AU  - Guo Q
AD  - Dept. of Pediatrics, the Second Hospital of Shandong University, Jinan, China.
FAU - Wang, Lihua
AU  - Wang L
AD  - Dept. of Pediatrics, the Second Hospital of Shandong University, Jinan, China.
FAU - Wang, Shandan
AU  - Wang S
AD  - Dept. of Pediatrics, the Second Hospital of Shandong University, Jinan, China.
FAU - Zhang, Xue
AU  - Zhang X
AD  - Dept. of Pediatrics, the Second Hospital of Shandong University, Jinan, China.
FAU - Wang, Yayun
AU  - Wang Y
AD  - Dept. of Pediatrics, the Second Hospital of Shandong University, Jinan, China.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Iran J Public Health
JT  - Iranian journal of public health
JID - 7505531
PMC - PMC4499082
OTO - NOTNLM
OT  - Carbamazepine
OT  - Efficacy
OT  - Epilepsy
OT  - Leviteracetam
OT  - Meta-analysis
EDAT- 2015/07/15 06:00
MHDA- 2015/07/15 06:01
PMCR- 2014/12/01
CRDT- 2015/07/15 06:00
PHST- 2014/08/19 00:00 [received]
PHST- 2014/10/25 00:00 [accepted]
PHST- 2015/07/15 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2015/07/15 06:01 [medline]
PHST- 2014/12/01 00:00 [pmc-release]
AID - ijph-43-1616 [pii]
PST - ppublish
SO  - Iran J Public Health. 2014 Dec;43(12):1616-26.